Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) stock fell -7.76% on Thursday to $0.82 against a previous-day closing price of $0.89. With 0.53 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.65 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.8800 whereas the lowest price it dropped to was $0.8200. The 52-week range on PIRS shows that it touched its highest point at $2.12 and its lowest point at $0.72 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 1.06.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PIRS was down-trending over the past week, with a drop of -4.51%, but this was up by 5.79% over a month. Three-month performance dropped to -41.01% while six-month performance fell -12.87%. The stock lost -50.60% in the past year, while it has lost -21.15% so far this year. A look at the trailing 12-month EPS for PIRS yields -0.56 with Next year EPS estimates of -0.67. For the next quarter, that number is -0.17. This implies an EPS growth rate of 36.70% for this year and 4.30% for next year.
Float and Shares Shorts:
At present, 74.52 million PIRS shares are outstanding with a float of 67.07 million shares on hand for trading. On Apr 27, 2023, short shares totaled 1.86 million, which was 2.50% higher than short shares on Mar 30, 2023. In addition to Mr. Stephen S. Yoder J.D. as the firm’s CEO, Pres & Director, Mr. Thomas Bures serves as its Sr. VP & CFO.
Institutional Ownership:
Through their ownership of 59.36% of PIRS’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 6.96% of PIRS, in contrast to 41.89% held by mutual funds. Shares owned by individuals account for 15.10%. As the largest shareholder in PIRS with 9.48% of the stake, Lynx1 Capital Management LP holds 7,067,718 shares worth 7,067,718. A second-largest stockholder of PIRS, BVF Partners LP, holds 5,080,320 shares, controlling over 6.82% of the firm’s shares. Aquilo Capital Management LLC is the third largest shareholder in PIRS, holding 4,552,876 shares or 6.11% stake. With a 1.43% stake in PIRS, the Candriam Equities L – Biotechnolo is the largest stakeholder. A total of 1,061,834 shares are owned by the mutual fund manager. The FCP Medical – BioHealth, which owns about 1.42% of PIRS stock, is the second-largest Mutual Fund holder. It holds 1,056,661 shares valued at 0.8 million. Vanguard Extended Market Index Fu holds 1.17% of the stake in PIRS, owning 872,701 shares worth 0.66 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, PIRS reported revenue of $3.70M and operating income of -$11.15M. The EBITDA in the recently reported quarter was -$10.56M and diluted EPS was -$0.14.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PIRS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With PIRS analysts setting a high price target of $7.00 and a low target of $7.00, the average target price over the next 12 months is $7.00. Based on these targets, PIRS could surge 753.66% to reach the target high and rise by 753.66% to reach the target low. Reaching the average price target will result in a growth of 753.66% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded PIRS stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.
